Sathi et al., “New Quinolines as Potential CNS Agents,” Arch. Pharm. 316, 767-772 (1983). |
Radzikowski et al., “New Antitumor Compounds. Biological studies. IV. Antitumor properties of 21 new acridine derivatives,” Acc. No. 1967: 401919 XP 002901810. |
Kozyreva et al., “Synthesis and Study of the Anthelmintic Acttivity of Some N-Heterocycles Containing 4-(4′-Diethylcarbamoyl-1′-Piperazinyl) Phenylamine Substituents,” Acc. No. 1972: 400153 XP 002901811. |
Klopman et al., “Computer-Automated Structure Evaluation of Antileukemic 9-Anilinoacridines,” Acc. No. 1987:628423 XP 002901812. |
Mikailitsyn F.S. et al., Medicinskaja Parazitologija 1 parazitarnye bolezni, vol. 5, pp. 55-57 (1991). |
Anti Haapalinna et al., “Evaluation of the effects of a specific α2-adrenoceptor antagonist, atipamozole, on α1- and α2-adrenoceptor subtype binding, brain neurochenistry and behaviour in comparison with yohimbine”, Naunyn-Schmiedeberg's Arch Pharmacol, vol. 356, pp. 570-582 (1997). |
Bruce Cain et al., “Potential Antitumor Agents. 23. 4′-(9-Acridinylamino)alkanesulfonanilide Congeners Bearing (Hydrophilic Functionality”, Journal of Medicinal Chemistry, vol. 20, No. 8, pp. 987-996 (1977). |
Adrienne Adams et al., “Interaction of DNA-Intercalating Antitumor Agents with Andrenoceptors”, Molecular Pharmacology, vol. 27, pp. 480-491 (1985). |
William Denny et al., “Pontetial Antitumor Agents. 36. Quantitative Relationships between Experimental Antitumor Activity, Toxicity, and Structure for the General Class of 9-Anilinoacridine Antitumor Agents”, J. Med. Chem., vol. 25, pp. 276-315 (1982). |
Anne Marjamäki et al., “Stable expression of recombinant human α2-adrenoceptor subtypes in two mammalian cell lines: characterization with [3H]rauwolscine binding, inhibition of adenylate cyclase and RNase protection assay”, Biochimica et Biophysica Acta, vol. 1134 pp. 169-177 (1992). |
Jeffrey Jasper et al., “Ligand Efficacy and Potency at Recombinant α2 Adrenergic Receptors”, Biochemical Pharmacology, vol. 55, pp. 1035-1043 (1998). |
Katariina Pohjanoksa et al., “α2-Adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase”, Eur. Journal of Pharmacology, vol. 335, pp. 53-63 (1997). |
Harry Scheinin et al., “Behavioural and neurochemical effects of antipamezole, a novel α2-adrenoceptor antagonist”, Eur. Journal of Pharmacology, vol. 151, pp. 35-42 (1988). |
Jukka Sallinen et al., “Genetic Alteration of α2c-Adrenoceptor Expression in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects of Dexmedetomine, a Subtype-Nonselective α2-Adrenoceptor Agonist”, Molecular Pharmacology, vol. 51 pp. 36-46 (1997). |
Sallinen et al., “Genetic alteration of the α2-adrenoceptor subtype c in mice effects the development of behavioral despair and stress-induced increases in plasma corticosterone levels”, Molecular Psychiatry, vol. 4, pp. 443-452 (1999). |
Timo Kauppila et al., “Effects of atipamezole, a novel α2-adrenoceptor antagonist, in open-field, plus-maze, two compartment exploratory, and forced swimming tests in the rat”, Eur. Journal of Pharmacology, vol. 205 pp. 117-182 (1991). |
Steven Southwick et al., “Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder”, Arch Gen. Psychiatry, vol. 54, pp. 749-758 (1997). |
Crawley et al., “Baseline Exploratory Activity Predicts Anxiolytic Responsiveness to Diazepam in Five Mouse Strains”, Brain Research Bulletin, vol. 8, pp. 609-612 (1982). |
Sallinen et al., “D-Amphetamine and L-5-Hydroxytryptophan-Induced Behaviours in mice with Genetically-Altered expression of the α2c-Adrenergic Receptor Subtype”, Neuroscience, vol. 86, No. 3, pp. 959-965 (1998). |
Jukka Sallinen et al., “Adrenergic α2c-Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice”, The Journal of Neuroscience, vol. 18 (8), pp. 3035-3042 (1998). |
Markus Björklund et al., “α2c-Adrenoceptor-Overexpressing Mice Are Impaired in Excuting Nonspatial Escape Strategies”, Molecular Pharmacology, vol. 54, pp. 569-576 (1998). |